LIQ861, Inhaled Treprostinil for PAH, Back Up for FDA Approval

LIQ861, Inhaled Treprostinil for PAH, Back Up for FDA Approval

294102

LIQ861, Inhaled Treprostinil for PAH, Back Up for FDA Approval

An updated application has been filed with the U.S. Food and Drug Administration (FDA), again asking that LIQ861 be approved as an inhalation treatment of pulmonary arterial hypertension (PAH), its developer Liquidia announced. The company first made this request in an application to the FDA submitted in April 2020. But the agency responded in November with a request for more data on the therapy and its use, in the form of complete response letter. FDA and Liquidia officials then…

You must be logged in to read/download the full post.